



Sosei Announces Filing of NDA for SOH-075 (NorLevo[®]) in Japan

Tokyo, Japan – 30 September 2009: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announces the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo[®]) to Ministry of Health, Labour and Welfare (MHLW) by Sosei Co. Ltd., its wholly owned Japanese subsidiary.

NorLevo[®] is an oral emergency contraceptive “morning after pill” which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo[®] contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse.

Sosei has acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA is supported by the data from Phase III study that was successfully completed in October 2008.

-Ends-

Enquiries:

Sosei Group Corporation

Tsuruya Hachiman Bldg. 5F, Kojimachi 2-4, Chiyoda-ku, Tokyo 102-0083 Japan
Hidetoshi Torami, Executive Officer
E-mail: htorami@sosei.com Tel: +81-3-5210-3399 Fax: +81-3-5210-3291

Editor’s notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit www.sosei.com